August 04, 2023 – We at thasso recently had an article (blog) on the much discussed and recently throughout the social media as wonder compound (drug) for weight loss promoted active ingredient Semaglutide in the form of the newly marketed product …

Is there living pharmacogenovigilance behind Semaglutide drugs? Read more »

August 26, 2022 – Traditionally, pharmacovigilance (PV), is the pharmaceutical science relating to the “collection, detection, assessment, monitoring, and prevention” of adverse drug reactions (ADRs) with pharmaceutical products and associated therapies. Pharmacovigilance is based on information about ADRs received from patients and healthcare …

Pharmacogenovigilance: Has the time come? Read more »

April 23, 2011 – In the history of flawed and/or market-withdrawn drugs, Lumiracoxib [Joicela], formely known as [Prexige], may only be a footnote, hardly comparable to the attention received by the high flying but ill-fated Rofecoxib [Vioxx], Troglitazone [Rezulin], and …

Could a biomarker rescue Lumiracoxib [Joicela], formerly known as [Prexige]? A genome-wide study identifies a strong assossiation of the HLA allele DQA1*0102 with Lumiracoxib [Joicela]-related serious liver injury Read more »

February 21, 2010 – In the field of pharmaco- and toxicogenetics of serious adverse drug reactions (sADRs) in humans, we learn today from a press release by the US Food and Drug Administration (FDA) of the completion and release by …

Regulatory Science Update: FDA and International Serious Adverse Events Consortium (SAEC) Complete Third Data Release Read more »